{"count": 2, "results": [{"_id": "34866061", "pmid": 34866061, "pmcid": "PMC8686174", "title": "The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3", "journal": "Endocrinol Diabetes Metab Case Rep", "authors": ["Sriravindrarajah A", "Fernandes A", "Wu T", "Hocking S"], "date": "2021-12-01T00:00:00Z", "doi": "10.1530/EDM-21-0102", "meta_date_publication": "2021 Dec 1", "meta_volume": "2021", "meta_issue": "", "meta_pages": "", "score": 50269.13, "text_hl": "The addition of a SGLT2 inhibitor to a pre-existing regimen of supramaximal doses of @CHEMICAL_Gliclazide @CHEMICAL_MESH:D005907 @@@gliclazide@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ immediately achieved excellent glycaemic control in a poorly controlled @<m>DISEASE_Maturity_Onset_Diabetes_of_the_Young_Type_3</m> @DISEASE_MESH:C563933 @@@MODY3@@@ @SPECIES_9606 @@@patient@@@. ", "citations": {"NLM": "Sriravindrarajah A, Fernandes A, Wu T, Hocking S. The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3 Endocrinol Diabetes Metab Case Rep. 2021 Dec 1;2021():. PMID: 34866061", "BibTeX": "@article{34866061, title={The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3}, author={Sriravindrarajah A and Fernandes A and Wu T and Hocking S}, journal={Endocrinol Diabetes Metab Case Rep}, volume={2021}}"}}, {"_id": "29429476", "pmid": 29429476, "title": "[Diagnosis and treatment of maturity onset diabetes of the young type 3].", "journal": "Ugeskr Laeger", "authors": ["Rose K", "Christensen AS", "Storgaard H", "Hædersdal S", "Hansen T", "Knop FK", "Vilsbøll T"], "date": "2018-02-05T00:00:00Z", "meta_date_publication": "2018 Feb 5", "meta_volume": "180", "meta_issue": "6", "meta_pages": "", "score": 50083.06, "text_hl": "When hypoglycaemia is a problem, short-acting @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulphonylureas@@@, @GENE_GLP1R @GENE_2740 @@@glucagon-like peptide-1 receptor@@@ agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, @CHEMICAL_Thiazolidinediones @CHEMICAL_MESH:D045162 @@@glitazones@@@ and sodium glucose transporter 2-inhibitors have only limited applicability in @<m>DISEASE_Maturity_Onset_Diabetes_of_the_Young_Type_3</m> @DISEASE_MESH:C563933 @@@MODY3@@@. ", "citations": {"NLM": "Rose K, Christensen AS, Storgaard H, Hædersdal S, Hansen T, Knop FK, Vilsbøll T. [Diagnosis and treatment of maturity onset diabetes of the young type 3]. Ugeskr Laeger. 2018 Feb 5;180(6):. PMID: 29429476", "BibTeX": "@article{29429476, title={[Diagnosis and treatment of maturity onset diabetes of the young type 3].}, author={Rose K and Christensen AS and Storgaard H and Hædersdal S and Hansen T and Knop FK and Vilsbøll T}, journal={Ugeskr Laeger}, volume={180}, number={6}}"}}]}